CMS assigns everlasting J-code for Savient’s KRYSTEXXA to treat RCG Savient Pharmaceuticals, Inc. The new J-code, J2507, was designated by the Centers for Medicare and Medicaid Solutions and will help simplify the billing and reimbursement procedure for prescribers of KRYSTEXXA, the first and just U.S. Food and Drug Administration approved treatment for refractory chronic gout . ‘The option of a long lasting J-code for KRYSTEXXA is a significant step toward ensuring that healthcare companies and their individuals with severe and debilitating gout, or RCG, have access to the first and just product for RCG,’ said John H. Johnson, LEADER President and Officer of Savient Pharmaceuticals..Building upon previous analysis, this finding helps clarify the role that inflammation plays in spurring tumor proliferation and draws attention to the want for a far more preventative strategy in fighting this inflammation. Inflammation, most of which was persistent, was common in benign prostate tissue, and was connected with prostate cancer positively, especially high grade, wrote the authors. This study works with an etiologic link between swelling and prostate carcinogenesis, and suggests an avenue for avoidance by mitigating intraprostatic irritation.